Abstract Library

#1608 Improving Outcomes for Patients with Resectable Small Bowel NET Tumours; Five Year Experience from a Tertiary Centre

Introduction: There remains controversy about which patients benefit from removal of their primary small bowel tumour and whether this should be performed in a specialist tertiary referral hospital as an elective procedure.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Elgendy K, Johnson S, French J, White S, Charnley R,

Keywords: small bowel, neuroendocrine tumors, surgical resection,

#1607 Perioperative Carcinoid Crisis During Surgery- Who Benefits from Octreotide?

Introduction: Carcinoid crisis, as an entity is poorly defined, but can be seen in patients with small bowel NET after open bowel surgery or tumour unrelated procedures as cardiovascular instability (CI)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Elgendy K, Johnson S, French J, White S, Charnley R,

Keywords: Octreotide, carcinoid crisis,

#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Hearn K, Teo L, Bernstone G, Johnson S, Perros P,

Keywords: neuroendocrine tumor, survival, Ki-67 proliferation index, metastatic disease,